Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure

Phase 1/2 Unknown 16 enrolled Kyoto University, Graduate School of Medicine

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether recombinant human hepatocyte growth factor is safe and effective in the treatment of fulminant and late-onset hepatic failure.

Timeline

Start: 2005-09
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HEPATOPOIETIN-A	Protein / enzyme biologic	—	—

Phase I/II Study of Recombinant Human Hepatocyte Growth Factor in Fulminant Hepatic Failure

Summary

Timeline

Drugs

Indications